1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients

Mark Poulsen Khurana,Isabelle Paula Lodding,Amanda Mocroft,Søren Schwartz Sørensen,Michael Perch,Allan Rasmussen,Finn Gustafsson,Jens D. Lundgren

1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients

2018

Mark Poulsen Khurana
Isabelle Paula Lodding
Amanda Mocroft
Søren Schwartz Sørensen
Michael Perch
Allan Rasmussen
Finn Gustafsson
Jens D. Lundgren

Background Rates and risk factors for cytomegalovirus (CMV) prophylaxis breakthrough and discontinuation were investigated, given uncertainty regarding optimal dosing for CMV primary (val)ganciclovir prophylaxis after solid organ transplantation (SOT).

Keywords:

Intensive care medicine
Organ transplantation
Disease
Ganciclovir
Medicine
Discontinuation
Valganciclovir
Internal medicine
Gastroenterology
Dosing
Proportional hazards model
Renal function
Transplantation
Hazard ratio

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations